0001185185-26-001313
SEC filingThis administrative amendment updates Anbio Biotechnology's regulatory status to a well-known seasoned issuer without altering any financial results or business operations for FY2025. The filing serves solely to correct the cover page classification, leaving the original April 7, 2026 report otherwise intact.
Anbio Biotechnology filed this Amendment No. 1 to Form 20-F on April 9, 2026, with a singular, narrow purpose: to correct the cover page classification to indicate that the company qualifies as a 'well-known seasoned issuer' (WKSI) under Rule 405 of the Securities Act. The original annual report for the fiscal year ended December 31, 2025, was filed just two days prior on April 7, 2026. This amendment does not reflect any events occurring after the original filing date, nor does it modify or update any disclosure other than the WKSI designation. Investors should interpret this filing as a technical compliance matter rather than a signal of any operational or financial shift.
The company explicitly stated that no changes were made to the financial statements or any other sections of the original annual report. This confirms that the financial position, results of operations, and cash flows previously reported for FY2025 remain authoritative. The amendment should be read in conjunction with the original Form 20-F, as this document does not stand alone as a complete report. The absence of any error correction or restatement markers provides assurance that the original filing's accounting integrity remains intact.
Anbio Biotechnology is incorporated in the Cayman Islands with principal executive offices in Frankfurt, Germany. The company maintains its classification as a non-accelerated filer and an emerging growth company, which relieves it from certain accelerated filing deadlines and auditor attestation requirements under Section 404(b) of the Sarbanes-Oxley Act. Financial statements are prepared in accordance with U.S. GAAP. Michael Lau, signing as Chief Executive Officer, authorized the filing, consistent with the company's disclosed leadership structure.